MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-04-03, EXEL has $2,593,593K in assets. $657,845K in debts. $226,152K in cash and cash equivalents.

Balance Sheets Overview

Current Ratio
325.80%
Quick Ratio
318.63%
Cash Ratio
60.96%
Debt to Asset Ratio
25.36%
Unit: Thousand (K) dollars
Assets Breakdown
    • Non-current marketable securitie...
    • Marketable securities
    • Trade receivables, net
    • Others
Liabilities Breakdown
    • Additional paid-in-capital
    • Accumulated deficit
    • Non-current operating lease liab...
    • Others

Balance Sheets
2026-04-03
2026-01-02
2025-10-03
2025-07-04
Cash and cash equivalents
226,152 482,488 376,300 164,433
Marketable securities
551,055 576,603 612,235 626,665
Trade receivables, net
328,947 286,916 309,725 292,354
Inventory
26,605 21,686 27,402 23,483
Prepaid expenses and other current assets
75,878 75,596 76,595 73,829
Total current assets
1,208,637 1,443,289 1,402,257 1,180,764
Non-current marketable securities
649,144 603,603 578,287 594,652
Property and equipment, net
95,524 98,960 104,748 110,314
Deferred tax assets, net
293,730 292,582 418,582 419,241
Goodwill
63,684 63,684 63,684 63,684
Right-of-use assets and other non-current assets
282,874 342,305 255,989 309,426
Total assets
2,593,593 2,844,423 2,823,547 2,678,081
Accounts payable
24,154 29,623 25,348 25,821
Accrued compensation and benefits
87,512 102,218 104,364 72,250
Accrued clinical trial liabilities
64,804 65,742 57,781 57,874
Rebates and fees due to customers
65,892 59,896 58,234 57,276
Accrued collaboration liabilities
28,327 22,783 23,428 21,525
Other current liabilities
100,286 125,382 104,622 101,365
Total current liabilities
370,975 405,644 373,777 336,111
Non-current operating lease liabilities
169,541 173,038 176,463 179,842
Other non-current liabilities
117,329 104,422 112,607 128,592
Total liabilities
657,845 683,104 662,847 644,545
Common stock, 0.001 par value 400,000 shares authorized issued and outstanding 253,701 and 262,483 at march 31, 2026, and december 31, 2025, respectively
254 262 268 270
Additional paid-in-capital
2,151,703 2,234,411 2,262,928 2,251,456
Accumulated other comprehensive income (loss)
-415 3,476 3,565 1,349
Accumulated deficit
-215,794 -76,830 -106,061 -219,539
Total stockholders equity
1,935,748 2,161,319 2,160,700 2,033,536
Total liabilities and stockholders equity
2,593,593 2,844,423 2,823,547 2,678,081
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities$551,055K (-34.98%↓ Y/Y)Trade receivables,net$328,947K (16.80%↑ Y/Y)Cash and cashequivalents$226,152K (23.07%↑ Y/Y)Prepaid expenses andother current assets$75,878K (29.27%↑ Y/Y)Inventory$26,605K (7.05%↑ Y/Y)Total current assets$1,208,637K (-13.45%↓ Y/Y)Non-current marketablesecurities$649,144K (4.80%↑ Y/Y)Deferred tax assets, net$293,730K (-29.90%↓ Y/Y)Right-of-use assets and othernon-current assets$282,874K (26.54%↑ Y/Y)Property and equipment,net$95,524K (-16.96%↓ Y/Y)Goodwill$63,684K (0.00%↑ Y/Y)Total assets$2,593,593K (-8.59%↓ Y/Y)Total liabilities andstockholders equity$2,593,593K (-8.59%↓ Y/Y)Total stockholdersequity$1,935,748K (-9.16%↓ Y/Y)Total liabilities$657,845K (-6.85%↓ Y/Y)Accumulated deficit-$215,794K (-32.15%↓ Y/Y)Accumulated othercomprehensive income (loss)-$415K (-120.65%↓ Y/Y)Additionalpaid-in-capital$2,151,703K (-6.12%↓ Y/Y)Total currentliabilities$370,975K (-7.05%↓ Y/Y)Non-current operating leaseliabilities$169,541K (-9.40%↓ Y/Y)Other non-currentliabilities$117,329K (-2.22%↓ Y/Y)Common stock, 0.001 parvalue 400,000 shares...$254K (-7.64%↓ Y/Y)Other currentliabilities$100,286K (-20.12%↓ Y/Y)Accrued compensationand benefits$87,512K (-2.49%↓ Y/Y)Rebates and fees due tocustomers$65,892K (13.92%↑ Y/Y)Accrued clinical trialliabilities$64,804K (12.44%↑ Y/Y)Accrued collaborationliabilities$28,327K (11.13%↑ Y/Y)Accounts payable$24,154K (-43.62%↓ Y/Y)

Exelixis-Logo-2023-svg

EXELIXIS, INC. (EXEL)

Exelixis-Logo-2023-svg

EXELIXIS, INC. (EXEL)